skip to main content

Attention:

The NSF Public Access Repository (NSF-PAR) system and access will be unavailable from 11:00 PM ET on Friday, November 15 until 2:00 AM ET on Saturday, November 16 due to maintenance. We apologize for the inconvenience.


This content will become publicly available on March 5, 2025

Title: Heparin Specifically Inhibits CRISPR/Cas12 Activation, Enabling Ultrasensitive Heparin Detection and Gene Editing Regulation
Award ID(s):
1933525
NSF-PAR ID:
10505592
Author(s) / Creator(s):
; ; ; ; ; ; ;
Publisher / Repository:
ACS Publications
Date Published:
Journal Name:
Analytical Chemistry
Volume:
96
Issue:
9
ISSN:
0003-2700
Page Range / eLocation ID:
3970 to 3978
Format(s):
Medium: X
Sponsoring Org:
National Science Foundation
More Like this
  1. null (Ed.)
    Recombinant heparin is produced by genetically engineered cells and provides an alternative to the current animal derived heparin. 
    more » « less
  2. Ionically complexed nanoparticles were prepared from an anionic polysaccharide drug, heparin, entrapped by a positively charged chitosan polysaccharide. In this study, the encapsulation of heparin was studied to optimize properties needed for its oral drug delivery. Chitosan, used in a variety of biomedical applications, was selected as a cationic polymer for heparin encapsulation. These particles were prepared with a slightly positive charge and an appropriate size for oral drug delivery. The release profiles of these ionically complexed nanoparticles were improved by using FDA approved stabilizers, such as pluronic non-ionic surfactant and polyvinyl alcohol. These results obtained in vitro suggest that these stabilized, ionically complexed nanoparticles may be well-suited for the oral drug delivery of heparin into the gastrointestinal tract. 
    more » « less